drugset / Trial / NCT04322669

Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)

NCT04322669 ↗

Phase 4 Completed 338 enrolled Almirall, S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy of pidotimod as treatment in participants with recurrent respiratory tract infections.

Timeline

Start
2021-08-04
Primary completion
2021-11-04
Completion
2021-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pidotimod Small molecule 400 mg Oral